Skip to main content

Table 4 Analysis of distribution of pathogens during study period

From: Effects of long-term use of macrolides in patients with non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled trials

Pathogens

No. of studies

Events/Total

Effect size

Heterogeneity

 

Macrolide

Control

OR(95%CI)

P

I 2 (%)

P

Eradication a

      

Anyb

3

39/104

28/99

1.76(0.91,3.41)

0.09

31

0.23

H. i

6

44/219

23/208

2.06(1.19,3.56)

0.01*

27

0.23

P. a

4

20/161

15/154

1.32(0.63,2.77)

0.46

0

0.63

S. a

3

5/106

7/102

0.69(0.22,2.12)

0.51

0

0.45

S. p

2

4/63

7/62

0.50(0.13,1.94)

0.32

38

0.20

M. c

3

13/130

4/122

2.95(0.99,8.87)

0.05*

38

0.20

Newly appearance

Anyb

4

28/163

36/157

0.68(0.37,1.23)

0.20

0

0.51

H. i

4

14/163

17/157

0.79(0.38,1.63)

0.52

61

0.05

P. a

2

6/105

6/103

0.98(0.32,3.02)

0.97

35

0.21

S. a

2

3/87

1/82

1.9(0.34,10.61)

0.47

47

0.17

S. \( {\mathrm{p}}_{=}^{\mathrm{d}} \)

1

2/46

0/45

5.11(0.24,109.51)

0.30

-

-

M. c

2

0/87

6/82

0.12(0.01,1.04)

0.05*

0

0.97

  1. Abbreviations: H. i, Haemophilus influenzae; P. a, Pseudomonas aerugiosa; S. a, Staphylococcus aureus; S. p, Streptococcus pneumoniae; M. c, Moraxella catarrhalis; OR (95%CI), Odds Ratio (95% confidential interval). aPathogens reported eradicated during study period; bany of the pathogens reported in the included studies; dThere was only one study reported S.p resistance, so Heterogeneity of this subgroup could not analysis; *It was suggestive of statistical significance.